Comparison of efficacy, safety, and tolerability of neoral vs sandimmun in de novo renal transplant patients over 24 months' treatment

被引:15
作者
Abendroth, D [1 ]
Buchholz, B [1 ]
Land, W [1 ]
May, G [1 ]
Wiesel, M [1 ]
Farber, L [1 ]
Korn, A [1 ]
Maibucher, A [1 ]
机构
[1] SANDOZ PHARMA AG, D-90327 NURNBERG, GERMANY
关键词
D O I
10.1016/S0041-1345(96)00091-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:275 / 276
页数:2
相关论文
共 5 条
[1]  
KOVARIK JM, 1994, TRANSPLANTATION, V58, P658
[2]   INFLUENCE OF CYCLOSPORINE PHARMACOKINETICS, TROUGH CONCENTRATIONS, AND AUC MONITORING ON OUTCOME AFTER KIDNEY-TRANSPLANTATION [J].
LINDHOLM, A ;
KAHAN, BD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (02) :205-218
[3]  
MEINZER A, 1993, LIFE, V4, P12
[4]   PHARMACOKINETICS AND TOLERABILITY OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN RENAL-ALLOGRAFT RECIPIENTS - A CONCENTRATION-CONTROLLED COMPARISON WITH THE COMMERCIAL FORMULATION [J].
MUELLER, EA ;
KOVARIK, JM ;
VANBREE, JB ;
LISON, AE ;
KUTZ, K .
TRANSPLANTATION, 1994, 57 (08) :1178-1182
[5]  
TAESCH S, 1994, TRANSPLANT INT S1, V7, P263